Pharma SHOCKER! Eli Lilly’s $17.5B Biotech Buyout RUMORS Send Shares SOARING 17.5% NOW!
Could a single biotech drug be worth a staggering $17.5 billion to a pharmaceutical giant? Eli Lilly is reportedly eyeing a massive €15 billion takeover of French biotech Abivax, causing Abivax shares to surge by 17.5% instantly. This intense interest primarily stems from Abivax's lead asset, obefazimod, a promising anti-inflammatory drug already showing positive Phase III results for ulcerative colitis and expected to become a future market leader. Unfolding at the J.P. Morgan Healthcare Conference 2026, this potential deal highlights a broader trend, as 2026 is already set for substantial M&A activity within the healthcare sector. Stay ahead of these crucial market shifts; subscribe to our channel for all the urgent updates.
Tags/Hashtags: #abivax #pharmaceuticals #obefazimod #abivax #msd
Leave a Reply